Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/SLC12A2_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/SLC12A2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/SLC12A2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/SLC12A2_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/SLC12A2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/SLC12A2_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/SLC12A2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/SLC12A2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/SLC12A2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/SLC12A2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/SLC12A2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00069708 | Skin | AK | response to osmotic stress | 20/1910 | 84/18723 | 2.37e-04 | 2.61e-03 | 20 |
GO:00716748 | Skin | AK | mononuclear cell migration | 35/1910 | 196/18723 | 7.20e-04 | 6.10e-03 | 35 |
GO:001003828 | Skin | AK | response to metal ion | 57/1910 | 373/18723 | 1.26e-03 | 9.52e-03 | 57 |
GO:00108182 | Skin | AK | T cell chemotaxis | 9/1910 | 28/18723 | 1.34e-03 | 1.00e-02 | 9 |
GO:003563316 | Skin | AK | maintenance of blood-brain barrier | 10/1910 | 35/18723 | 2.00e-03 | 1.35e-02 | 10 |
GO:00321024 | Skin | AK | negative regulation of response to external stimulus | 61/1910 | 420/18723 | 2.96e-03 | 1.87e-02 | 61 |
GO:00726762 | Skin | AK | lymphocyte migration | 22/1910 | 117/18723 | 3.41e-03 | 2.08e-02 | 22 |
GO:000836110 | Skin | AK | regulation of cell size | 30/1910 | 181/18723 | 5.22e-03 | 2.91e-02 | 30 |
GO:007124118 | Skin | AK | cellular response to inorganic substance | 35/1910 | 226/18723 | 8.09e-03 | 4.07e-02 | 35 |
GO:007124818 | Skin | AK | cellular response to metal ion | 31/1910 | 197/18723 | 9.73e-03 | 4.72e-02 | 31 |
GO:0042060111 | Skin | SCCIS | wound healing | 63/919 | 422/18723 | 2.26e-15 | 6.00e-12 | 63 |
GO:003059515 | Skin | SCCIS | leukocyte chemotaxis | 33/919 | 230/18723 | 3.03e-08 | 7.00e-06 | 33 |
GO:005090016 | Skin | SCCIS | leukocyte migration | 44/919 | 369/18723 | 4.93e-08 | 8.19e-06 | 44 |
GO:006032615 | Skin | SCCIS | cell chemotaxis | 39/919 | 310/18723 | 6.84e-08 | 1.04e-05 | 39 |
GO:0007568110 | Skin | SCCIS | aging | 41/919 | 339/18723 | 9.54e-08 | 1.29e-05 | 41 |
GO:006104119 | Skin | SCCIS | regulation of wound healing | 21/919 | 134/18723 | 2.31e-06 | 1.17e-04 | 21 |
GO:007167413 | Skin | SCCIS | mononuclear cell migration | 25/919 | 196/18723 | 1.19e-05 | 4.10e-04 | 25 |
GO:007267811 | Skin | SCCIS | T cell migration | 13/919 | 66/18723 | 1.60e-05 | 4.98e-04 | 13 |
GO:1903034110 | Skin | SCCIS | regulation of response to wounding | 22/919 | 167/18723 | 2.36e-05 | 6.65e-04 | 22 |
GO:19908682 | Skin | SCCIS | response to chemokine | 15/919 | 97/18723 | 7.36e-05 | 1.71e-03 | 15 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0511014 | Breast | Precancer | Vibrio cholerae infection | 14/684 | 50/8465 | 2.67e-05 | 2.64e-04 | 2.02e-04 | 14 |
hsa0511015 | Breast | Precancer | Vibrio cholerae infection | 14/684 | 50/8465 | 2.67e-05 | 2.64e-04 | 2.02e-04 | 14 |
hsa0511022 | Breast | IDC | Vibrio cholerae infection | 17/867 | 50/8465 | 4.82e-06 | 6.82e-05 | 5.10e-05 | 17 |
hsa049704 | Breast | IDC | Salivary secretion | 18/867 | 93/8465 | 5.69e-03 | 3.13e-02 | 2.34e-02 | 18 |
hsa0511032 | Breast | IDC | Vibrio cholerae infection | 17/867 | 50/8465 | 4.82e-06 | 6.82e-05 | 5.10e-05 | 17 |
hsa0497011 | Breast | IDC | Salivary secretion | 18/867 | 93/8465 | 5.69e-03 | 3.13e-02 | 2.34e-02 | 18 |
hsa0511041 | Breast | DCIS | Vibrio cholerae infection | 17/846 | 50/8465 | 3.45e-06 | 4.45e-05 | 3.28e-05 | 17 |
hsa0511051 | Breast | DCIS | Vibrio cholerae infection | 17/846 | 50/8465 | 3.45e-06 | 4.45e-05 | 3.28e-05 | 17 |
hsa05110 | Colorectum | AD | Vibrio cholerae infection | 29/2092 | 50/8465 | 5.10e-07 | 7.12e-06 | 4.54e-06 | 29 |
hsa04972 | Colorectum | AD | Pancreatic secretion | 36/2092 | 102/8465 | 1.06e-02 | 3.98e-02 | 2.54e-02 | 36 |
hsa051101 | Colorectum | AD | Vibrio cholerae infection | 29/2092 | 50/8465 | 5.10e-07 | 7.12e-06 | 4.54e-06 | 29 |
hsa049721 | Colorectum | AD | Pancreatic secretion | 36/2092 | 102/8465 | 1.06e-02 | 3.98e-02 | 2.54e-02 | 36 |
hsa051102 | Colorectum | SER | Vibrio cholerae infection | 24/1580 | 50/8465 | 2.17e-06 | 3.13e-05 | 2.28e-05 | 24 |
hsa049722 | Colorectum | SER | Pancreatic secretion | 30/1580 | 102/8465 | 5.41e-03 | 3.28e-02 | 2.38e-02 | 30 |
hsa051103 | Colorectum | SER | Vibrio cholerae infection | 24/1580 | 50/8465 | 2.17e-06 | 3.13e-05 | 2.28e-05 | 24 |
hsa049723 | Colorectum | SER | Pancreatic secretion | 30/1580 | 102/8465 | 5.41e-03 | 3.28e-02 | 2.38e-02 | 30 |
hsa051104 | Colorectum | MSS | Vibrio cholerae infection | 27/1875 | 50/8465 | 8.58e-07 | 1.20e-05 | 7.34e-06 | 27 |
hsa049724 | Colorectum | MSS | Pancreatic secretion | 33/1875 | 102/8465 | 1.09e-02 | 3.75e-02 | 2.30e-02 | 33 |
hsa051105 | Colorectum | MSS | Vibrio cholerae infection | 27/1875 | 50/8465 | 8.58e-07 | 1.20e-05 | 7.34e-06 | 27 |
hsa049725 | Colorectum | MSS | Pancreatic secretion | 33/1875 | 102/8465 | 1.09e-02 | 3.75e-02 | 2.30e-02 | 33 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC12A2 | SNV | Missense_Mutation | | c.2921N>T | p.Thr974Ile | p.T974I | P55011 | protein_coding | tolerated(0.35) | benign(0) | TCGA-A8-A08S-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
SLC12A2 | SNV | Missense_Mutation | | c.2813T>C | p.Leu938Ser | p.L938S | P55011 | protein_coding | tolerated(0.28) | benign(0.115) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC12A2 | SNV | Missense_Mutation | rs772305204 | c.1461N>G | p.Phe487Leu | p.F487L | P55011 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-BH-A0B5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | CR |
SLC12A2 | SNV | Missense_Mutation | | c.985N>A | p.Val329Ile | p.V329I | P55011 | protein_coding | tolerated(0.06) | probably_damaging(0.99) | TCGA-BH-A0HL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
SLC12A2 | SNV | Missense_Mutation | rs111986207 | c.2739A>G | p.Ile913Met | p.I913M | P55011 | protein_coding | tolerated(0.27) | benign(0.097) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC12A2 | SNV | Missense_Mutation | | c.1593N>T | p.Leu531Phe | p.L531F | P55011 | protein_coding | tolerated(0.06) | benign(0.401) | TCGA-E9-A1RH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | SD |
SLC12A2 | SNV | Missense_Mutation | | c.1594N>A | p.Val532Ile | p.V532I | P55011 | protein_coding | tolerated(0.24) | possibly_damaging(0.728) | TCGA-E9-A1RH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | SD |
SLC12A2 | SNV | Missense_Mutation | novel | c.1070C>T | p.Ser357Phe | p.S357F | P55011 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-XX-A89A-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC12A2 | insertion | In_Frame_Ins | novel | c.1124_1125insAGATTTTATTTACTCTTTTTCCAGTTT | p.Ala375_Asn376insAspPheIleTyrSerPheSerSerPhe | p.A375_N376insDFIYSFSSF | P55011 | protein_coding | | | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | | SD |
SLC12A2 | SNV | Missense_Mutation | | c.1129G>A | p.Ala377Thr | p.A377T | P55011 | protein_coding | deleterious(0.04) | probably_damaging(0.996) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6558 | SLC12A2 | DRUGGABLE GENOME, TRANSPORTER, EXTERNAL SIDE OF PLASMA MEMBRANE | | BUMETANIDE | BUMETANIDE | |
6558 | SLC12A2 | DRUGGABLE GENOME, TRANSPORTER, EXTERNAL SIDE OF PLASMA MEMBRANE | | BUMETANIDE | BUMETANIDE | |
6558 | SLC12A2 | DRUGGABLE GENOME, TRANSPORTER, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | 178101453 | PIRETANIDE | |
6558 | SLC12A2 | DRUGGABLE GENOME, TRANSPORTER, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | 178101539 | BUMETANIDE | |
6558 | SLC12A2 | DRUGGABLE GENOME, TRANSPORTER, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | 178101541 | FUROSEMIDE | |